Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients... | April 11, 2023